Rosa-Rosa Juan Manuel, Pita Guillermo, Urioste Miguel, Llort Gemma, Brunet Joan, Lázaro Conxi, Blanco Ignacio, Ramón y Cajal Teresa, Díez Orland, de la Hoya Miguel, Caldés Trinidad, Tejada Maria-Isabel, González-Neira Anna, Benítez Javier
Human Cancer Genetics Programme, Spanish National Cancer Research Centre, 28029 Madrid, Spain.
Am J Hum Genet. 2009 Feb;84(2):115-22. doi: 10.1016/j.ajhg.2008.12.013. Epub 2009 Jan 15.
Despite all the research efforts made during the last few decades, most of the cases of families with breast cancer remain unexplained. Mutations in BRCA1 and BRCA2, and in other breast-cancer-susceptibility genes, account for about 25% of familial breast cancer. Linkage studies have failed to identify other breast-cancer-susceptibility genes. The selection criteria of the families, differences in the population background, or clinical and genetic heterogeneity, among other factors, might determine the power to detect the linkage signal. We have performed a SNP-based linkage scan with a total of 6000 SNP markers across the genome in 41 breast-cancer Spanish families, with an average of four breast-cancer cases per family not associated with BRCA1 or BRCA2 germline mutations. In addition, we have included three BRCA-positive families to test the power in linkage detection from a low-complexity family in which a high-penetrance mutation segregates. We have identified three regions of interest, located on 3q25, 6q24, and 21q22. The two former regions showed a suggestive linkage signal (HLOD scores 3.01 and 2.26, respectively), and the latter region showed a significant linkage signal (HLOD score 3.55). Moreover, we found that a subset of 13 families with bilateral breast cancer presented a HLOD of 3.13 on the 3q25 region. Our results suggest that several variables must be taken into account before performing a linkage study in familial breast cancer because of the high heterogeneity within non-BRCA1/2 families. Phenotypic and geographic homogeneity could be the most important factors.
尽管在过去几十年中进行了大量研究工作,但大多数乳腺癌家族病例的病因仍不明确。BRCA1和BRCA2以及其他乳腺癌易感基因的突变约占家族性乳腺癌的25%。连锁研究未能确定其他乳腺癌易感基因。家族的选择标准、人群背景差异、临床和遗传异质性等因素可能决定检测连锁信号的能力。我们对41个西班牙乳腺癌家族进行了全基因组单核苷酸多态性(SNP)连锁扫描,共使用了6000个SNP标记,每个家族平均有4例乳腺癌病例,且与BRCA1或BRCA2种系突变无关。此外,我们纳入了3个BRCA阳性家族,以测试在一个高外显率突变分离的低复杂性家族中进行连锁检测的能力。我们确定了三个感兴趣的区域,分别位于3q25、6q24和21q22。前两个区域显示出提示性连锁信号(HLOD分数分别为3.01和2.26),后一个区域显示出显著连锁信号(HLOD分数为3.55)。此外,我们发现13个双侧乳腺癌家族的一个子集在3q25区域的HLOD为3.13。我们的结果表明,由于非BRCA1/2家族内部高度异质性,在进行家族性乳腺癌连锁研究之前必须考虑几个变量。表型和地理同质性可能是最重要的因素。